(Post-pandemic Era) - Global Antisense and RNAi Therapeutics Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type 2021

(Post-pandemic Era) - Global Antisense and RNAi Therapeutics Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type 2021

Table of Contents

Global Antisense and RNAi Therapeutics Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 RNA interference -Product Introduction and Major Manufacturers
1.1.2 SiRNA -Product Introduction and Major Manufacturers
1.1.3 MiRNA -Product Introduction and Major Manufacturers
1.1.4 Antisense RNA -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
2.1 Regional Market Share in Terms of Production (2020-2027)
2.2 Regional Market Share in Terms of Revenue (2020-2027)
2.3 Regional Market Share in Terms of Consumption (2020-2027)
3 Global Antisense and RNAi Therapeutics Market Assessment by Type
3.1 Global Antisense and RNAi Therapeutics Production by Type (2016-2027)
3.2 Global Antisense and RNAi Therapeutics Revenue by Type (2016-2027)
3.3 North America Antisense and RNAi Therapeutics Production and Revenue by Type (2016-2027)
3.4 Asia Antisense and RNAi Therapeutics Production and Revenue by Type (2016-2027)
3.5 Europe Antisense and RNAi Therapeutics Production and Revenue by Type (2016-2027)
3.6 Middle East & Africa Antisense and RNAi Therapeutics Production and Revenue by Type (2016-2027)
3.7 South America Antisense and RNAi Therapeutics Production and Revenue by Type (2016-2027)
4 Global Antisense and RNAi Therapeutics Market Assessment by Application
4.1 Historical & Forecast Global Antisense and RNAi Therapeutics Consumption, Different Application Field (2016-2027)
4.2 Historical & Forecast North America Antisense and RNAi Therapeutics Consumption, Different Application Field (2016-2027)
4.3 Historical & Forecast Asia Antisense and RNAi Therapeutics Consumption, Different Application Field (2016-2027)
4.4 Historical & Forecast Europe Antisense and RNAi Therapeutics Consumption, Different Application Field (2016-2027)
4.5 Historical & Forecast Middle East & Africa Antisense and RNAi Therapeutics Consumption, Different Application Field (2016-2027)
4.6 Historical & Forecast South America Antisense and RNAi Therapeutics Consumption, Different Application Field (2016-2027)
5 North America
5.1 US Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
5.2 Canada Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
5.3 Mexico Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
6 Asia
6.1 China Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
6.2 Japan Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
6.3 India Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
6.4 Korea Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
6.5 Southeat Asia Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
7 Europe
7.1 Germany Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
7.2 UK Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
7.3 France Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
7.4 Russia Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
7.5 Italy Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
8 Middle East and Africa
8.1 Saudi Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
8.2 UAE Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
8.3 Egypt Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
8.4 Nigeria Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
8.5 South Africa Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
9 South America
9.1 Brazil Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
9.2 Argentina Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
9.3 Colombia Antisense and RNAi Therapeutics Capacity, Production, Consumption and Proportion of Products Sold (2016-2027)
10 Global Antisense and RNAi Therapeutics Average Price Trend
10.1 Market Price for Each Type of Antisense and RNAi Therapeutics in North America (2016-2027)
10.2 Market Price for Each Type of Antisense and RNAi Therapeutics in Asia (2016-2027)
10.3 Market Price for Each Type of Antisense and RNAi Therapeutics in Europe (2016-2027)
10.4 Market Price for Each Type of Antisense and RNAi Therapeutics in Middle East & Africa (2016-2027)
10.5 Market Price for Each Type of Antisense and RNAi Therapeutics in South America (2016-2027)
11 Value Chain (Impact of COVID-19)
11.1 Antisense and RNAi Therapeutics Value Chain Analysis
11.1.1 Upstream
11.1.2 Downstream
11.2 COVID-19 Impact on Antisense and RNAi Therapeutics Industry
11.2.1 Industrial Policy Issued Under the Epidemic Situation
11.3 Cost-Under the Epidemic Situation
11.3.1 Cost of Raw Material
11.4 Channel Analysis
11.4.1 Distribution Channel-Under the Epidemic Situation
11.4.2 Distributors
12 Antisense and RNAi Therapeutics Competitive Analysis
12.1 Glaxo Smith Kline
12.1.1 Glaxo Smith Kline Company Profiles
12.1.2 Glaxo Smith Kline Product Introduction
12.1.3 Glaxo Smith Kline Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.1.4 SWOT Analysis
12.2 Sanofi Aventis / Genzyme
12.2.1 Sanofi Aventis / Genzyme Company Profiles
12.2.2 Sanofi Aventis / Genzyme Product Introduction
12.2.3 Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.2.4 SWOT Analysis
12.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
12.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Profiles
12.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Product Introduction
12.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.3.4 SWOT Analysis
12.4 Arbutus Biopharma Ltd.
12.4.1 Arbutus Biopharma Ltd. Company Profiles
12.4.2 Arbutus Biopharma Ltd. Product Introduction
12.4.3 Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.4.4 SWOT Analysis
12.5 Quark Pharmaceuticals
12.5.1 Silence Therapeutics Company Profiles
12.5.2 Silence Therapeutics Product Introduction
12.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.5.4 SWOT Analysis
12.6 Bio-Path Holdings Inc.
12.6.1 Bio-Path Holdings Inc. Company Profiles
12.6.2 Bio-Path Holdings Inc. Product Introduction
12.6.3 Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.6.4 SWOT Analysis
12.7 Calando Pharmaceuticals
12.7.1 Calando Pharmaceuticals Company Profiles
12.7.2 Calando Pharmaceuticals Product Introduction
12.7.3 Calando Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.7.4 SWOT Analysis
12.8 ICo Therapeutics
12.8.1 ICo Therapeutics Company Profiles
12.8.2 ICo Therapeutics Product Introduction
12.8.3 ICo Therapeutics Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.8.4 SWOT Analysis
12.9 Quark Pharmaceuticals
12.9.1 Quark Pharmaceuticals Company Profiles
12.9.2 Quark Pharmaceuticals Product Introduction
12.9.3 Quark Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.9.4 SWOT Analysis
12.10 Rexhan Pharmaceuticals
12.10.1 Rexhan Pharmaceuticals Company Profiles
12.10.2 Rexhan Pharmaceuticals Product Introduction
12.10.3 Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue (2015-2020)
12.10.4 SWOT Analysis
12.11 Biomarin/Prosensa
12.12 Regulus Therapeutics
12.13 Rxi Pharmaceuticals
12.14 Silenseed
12.15 Dicerna Pharmaceuticals
12.16 Sirnaomics Inc
13 Conclusion

List of Tables and Figures

Figure Product Introduction
Table Production (K Units) and Revenue (Million USD) of Major Players (2016-2020)
Figure Global Antisense and RNAi Therapeutics Production Market Share of Top 5 Players
Table CAGR of Major Market (2021-2026)
Table CAGR in Terms of Production of Each Type (2016-2027)
Table Regional Market Share in Terms of Production (2020-2027)
Figure Regional Market Share in Terms of Production (2019 - 2020)
Table Regional Market Share in Terms of Revenue (2020-2027)
Figure Regional Market Share in Terms of Revenue (2019 - 2020)
Figure Regional Market Share in Terms of Consumption (2019 - 2020)
Figure Regional Market Share in Terms of Consumption (2019 - 2020)
Table Global Antisense and RNAi Therapeutics Production (K Unit) by Type (2016-2027)
Figure Global Antisense and RNAi Therapeutics Production (K Unit) and Growth Rate (2016-2027)
Figure Global Antisense and RNAi Therapeutics Production Market Share (%) by Type (2019 -2020)
Table Global Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2016-2027)
Figure Global Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2016-2027)
Figure Global Antisense and RNAi Therapeutics Revenue Market Share (%) by Type (2019-2020)
Figure North America Antisense and RNAi Therapeutics Production (K Unit) by Type (2016-2027)
Figure North America Antisense and RNAi Therapeutics Production (K Unit) and Growth Rate (2016-2027)
Figure North America Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2016-2027)
Figure North America Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2016-2027)
Figure Asia Antisense and RNAi Therapeutics Production (K Unit) by Type (2016-2027)
Figure Asia Antisense and RNAi Therapeutics Production (K Unit) and Growth Rate (2016-2027)
Figure Asia Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2016-2027)
Figure Asia Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2016-2027)
Figure Europe Antisense and RNAi Therapeutics Production (K Unit) by Type (2016-2027)
Figure Europe Antisense and RNAi Therapeutics Production (K Unit) and Growth Rate (2016-2027)
Figure Europe Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2016-2027)
Figure Europe Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2016-2027)
Figure Middle East & Africa Antisense and RNAi Therapeutics Production (K Unit) by Type (2016-2027)
Figure Middle East & Africa Antisense and RNAi Therapeutics Production (K Unit) and Growth Rate (2016-2027)
Figure Middle East & Africa Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2016-2027)
Figure Middle East & Africa Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2016-2027)
Figure South America Antisense and RNAi Therapeutics Production (K Unit) by Type (2016-2027)
Figure South America Antisense and RNAi Therapeutics Production (K Unit) and Growth Rate (2016-2027)
Figure South America Antisense and RNAi Therapeutics Revenue (Million USD) by Type (2016-2027)
Figure South America Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2016-2027)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Figure Consumption (K Unit) and Growth Rate (2016-2027)
Figure Different Application Field Consumption Market Share (%) (2019-2020)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Figure North America Antisense and RNAi Therapeutics Consumption (K Unit) and Growth Rate (2016-2027)
Figure North America Antisense and RNAi Therapeutics Consumption Market Share (%) by Application (2016-2027)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Figure Asia Antisense and RNAi Therapeutics Consumption (K Unit) and Growth Rate (2016-2027)
Figure Asia Antisense and RNAi Therapeutics Consumption Market Share (%) by Application (2016-2027)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Figure Europe Antisense and RNAi Therapeutics Consumption (K Unit) and Growth Rate (2016-2027)
Figure Europe Antisense and RNAi Therapeutics Consumption Market Share (%) by Application (2016-2027)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Figure Middle East & Africa Antisense and RNAi Therapeutics Consumption (K Unit) and Growth Rate (2016-2027)
Figure Middle East & Africa Antisense and RNAi Therapeutics Consumption Market Share (%) by Application (2016-2027)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Figure South America Antisense and RNAi Therapeutics Consumption (K Unit) and Growth Rate (2016-2027)
Figure South America Antisense and RNAi Therapeutics Consumption Market Share (%) by Application (2016-2027)
Table Historical & Forecast Antisense and RNAi Therapeutics Different Application Field Consumption (K Unit)
Table US Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Canada Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Mexico Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table China Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Japan Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table India Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Korea Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Southeast Asia Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Germany Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table UK Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table France Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Russia Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Italy Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Saudi Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table UAE Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Egypt Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Nigeria Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table South Africa Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Brazil Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Argentina Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Colombia Antisense and RNAi Therapeutics Capacity (K Units), Production (K Units) and Consumption (K Units) (2016-2027) and Proportion of Products Sold
Figure Proportion of Products Sold (%) (2015 -2026)
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in China
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in EU
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in USA
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in Japan
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in India
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in Southeast Asia
Table Market Price (USD/Unit) for Each Type of Antisense and RNAi Therapeutics in South America
Figure Value Chain Structure of Antisense and RNAi Therapeutics
Table Value Chain
Table Key Suppliers of Raw Material/Components
Table Key Downstream Customer in Each Application Field
Table Industry News List of Antisense and RNAi Therapeutics
Figure Cost Structure of Antisense and RNAi Therapeutics in 2020
Table Distributors/Traders List
Table Glaxo Smith Kline Profiles
Table Glaxo Smith Kline Antisense and RNAi Therapeutics Product Introduction
Figure Glaxo Smith Kline Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Glaxo Smith Kline SWOT Analysis
Table Sanofi Aventis / Genzyme Profiles
Table Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Product Introduction
Figure Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Sanofi Aventis / Genzyme SWOT Analysis
Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Profiles
Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction
Figure Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Isis Pharmaceuticals/ Ionis Pharmaceuticals SWOT Analysis
Table Arbutus Biopharma Ltd. Profiles
Table Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Product Introduction
Figure Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Arbutus Biopharma Ltd. SWOT Analysis
Table Silence Therapeutics Profiles
Table Silence Therapeutics Antisense and RNAi Therapeutics Product Introduction
Figure Silence Therapeutics Medical Devices & Consumables Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Silence Therapeutics SWOT Analysis
Table Bio-Path Holdings Inc. Profiles
Table Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Product Introduction
Figure Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Bio-Path Holdings Inc. SWOT Analysis
Table Calando Pharmaceuticals Profiles
Table Calando Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction
Figure Calando Pharmaceuticals Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Calando Pharmaceuticals SWOT Analysis
Table ICo Therapeutics Profiles
Table ICo Therapeutics Antisense and RNAi Therapeutics Product Introduction
Figure ICo Therapeutics Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure ICo Therapeutics SWOT Analysis
Table Quark Pharmaceuticals Profiles
Table Quark Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction
Figure Quark Pharmaceuticals Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Quark Pharmaceuticals SWOT Analysis
Table Rexhan Pharmaceuticals Profiles
Table Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction
Figure Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Rexhan Pharmaceuticals SWOT Analysis
Table Biomarin/Prosensa Profiles
Table Biomarin/Prosensa Antisense and RNAi Therapeutics Product Introduction
Figure Biomarin/Prosensa Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Biomarin/Prosensa SWOT Analysis
Table Regulus Therapeutics Profiles
Table Regulus Therapeutics Antisense and RNAi Therapeutics Product Introduction
Figure Regulus Therapeutics Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Regulus Therapeutics SWOT Analysis
Table Rxi Pharmaceuticals Profiles
Table Rxi Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction
Figure Rxi Pharmaceuticals Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Rxi Pharmaceuticals SWOT Analysis
Table Silenseed Profiles
Table Silenseed Antisense and RNAi Therapeutics Product Introduction
Figure Silenseed Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Silenseed SWOT Analysis
Table Dicerna Pharmaceuticals Profiles
Table Dicerna Pharmaceuticals Antisense and RNAi Therapeutics Product Introduction
Figure Dicerna Pharmaceuticals Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)
Figure Dicerna Pharmaceuticals SWOT Analysis
Table Sirnaomics Inc Profiles
Table Sirnaomics Inc Antisense and RNAi Therapeutics Product Introduction
Figure Sirnaomics Inc Antisense and RNAi Therapeutics Capacity (Unit), Production (Unit), Revenue (Million USD) (2015-2020)

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Targeted RNA Sequencing Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 71

Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing The ability to detect both known and novel gene fusion partners in many sample types. In The report, we ......

Global Targeted RNA Sequencing Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 87

According to our LPI (LP Information) latest study, the global Targeted RNA Sequencing market size was valued at US$ 1761.4 million in 2023. With growing demand in downstream market, the Targeted RNA Sequencing is forecast to a readjusted size of US$ 7649.2 million by 2030 with a CAGR of 23.3% during review period. The research report highlights the growth potential of the global Targeted RNA Sequencing market. Targeted RNA Sequencing are expected to show stable growth in the future mark......

Global Targeted RNA Sequencing Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 94

According to our (Global Info Research) latest study, the global Targeted RNA Sequencing market size was valued at USD 1852.7 million in 2023 and is forecast to a readjusted size of USD 7255.4 million by 2030 with a CAGR of 21.5% during review period. Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or ......

Global Antisense and RNAi Therapeutics Market Research Report 2023, Forecast to 2028

Published: 26-Dec-2023        Price: US 2680 Onwards        Pages: 133

Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (millio......

Global Antisense and RNAi Therapeutics Professional Survey Report 2023, Forecast to 2028

Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 101

Antisense therapy means the selective, sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs in response to dsRNA. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (millio......

Global Targeted RNA Sequencing Market Research Report 2023, Forecast to 2028

Published: 13-Nov-2023        Price: US 2680 Onwards        Pages: 137

Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest.  Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......

Global Targeted RNA Sequencing Professional Survey Report 2023, Forecast to 2028

Published: 13-Nov-2023        Price: US 3280 Onwards        Pages: 100

Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest.  Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......

Global RNAi for Therapeutic Market Status and Outlook 2023-2028

Published: 08-Nov-2023        Price: US 3160 Onwards        Pages: 106

RNAi is a fundamental cellular mechanism for silencing gene expression that can be harnessed for the development of new drugs Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product ......

Global RNAi for Therapeutic Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 24-Oct-2023        Price: US 3380 Onwards        Pages: 104

Market Overview of Global RNAi for Therapeutic market: According to our latest research, the global RNAi for Therapeutic market looks promising in the next 5 years. As of 2022, the global RNAi for Therapeutic market was estimated at USD 260.55 million, and it's anticipated to reach USD 3633.33 million in 2028, with a CAGR of 55.14% during the forecast years. RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs